-
Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective
Wednesday, June 19, 2019 - 10:22am | 408Read More...Shares of the small-cap, actively traded Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) were seeing positive momentum Wednesday on top of the 8.08% gain the stock recorded Tuesday. What Happened Ironwood and Allergan plc (NYSE: AGN) announced positive topline results from a Phase 3b study...
-
Ironwood's Pipeline Needs Work, Analyst Downgrades
Friday, July 21, 2017 - 10:47am | 312Read More...Analysts at JPMorgan no longer hold a bullish view on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) after the company released top-line results from a phase 2b trial called IW-3718. The firm's Anupam Rama downgraded Ironwood's stock from Overweight to Neutral with a price target lowered...
-
Takeda's Speculative Interest In Synergy Soothes Stomach Pains; Canaccord Says Buy
Wednesday, January 25, 2017 - 3:55pm | 366Read More...Canaccord Genuity said it views Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY)’s speculated interest in buying Synergy Pharmaceuticals Inc (NASDAQ: SGYP) as a positive step. The potential deal could boost its GI (gastrointestine) portfolio. Speculative Interest Commenting on the indication...
-
JPMorgan On Allergan: Solid Core Product Performance
Wednesday, May 11, 2016 - 9:14am | 297Read More...JPMorgan has maintained its Overweight rating on Allergan plc Ordinary Shares (NYSE: AGN), saying that the double-digit growth in the company's brands business is expected to continue throughout the year. Allergan's first quarter adjusted earnings of $3.04 a share topped the Street's estimate of $3...
-
Citi Maintains Its Constructive Stance On Allergan
Wednesday, May 11, 2016 - 9:01am | 299Read More...Citi has maintained its Buy rating on Allergan plc Ordinary Shares (NYSE: AGN), saying the performance of the core brands "should not be overlooked." Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1...
-
Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)
Wednesday, March 11, 2015 - 9:10am | 227Read More...In a report published Tuesday, Citigroup analyst Liav Abraham commented on a recent meeting with Actavis plc's (NYSE: ACT) senior management team in London that increased his confidence in a "swift and successful" integration of Allergan, Inc. Abraham noted that key growth...
-
Forest Labs To Acquire Furiex Pharma A Deal Potentially Worth $1.46 Billion
Monday, April 28, 2014 - 4:44pm | 248Read More...This afternoon, Forest Laboratories (NYSE: FRX) said that it would buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion in cash, and rights. This deal also includes milestone payments to access Furiex's promising treatment for irritable bowel syndrome (IBS). “The acquisition of...
